[{"nct_id":["NCT04119440"],"intervention":["Low Dose"],"study_type":["Interventional"],"start_date":["May 2020"],"compl_date":["December 2021"],"phase":["Phase 1"],"trial_arms":["Low Dose | High Dose | Placebo"],"cond":["MERS (Middle East Respiratory Syndrome)"]},{"nct_id":["NCT04244591"],"intervention":["standard care"],"study_type":["Interventional"],"start_date":["January 26, 2020"],"compl_date":["December 25, 2020"],"phase":["Phase 2/Phase 3"],"trial_arms":["standard care | standard care + methylprednisolone therapy"],"cond":["Coronavirus Infections"]},{"nct_id":["NCT04244591"],"intervention":["standard care"],"study_type":["Interventional"],"start_date":["January 26, 2020"],"compl_date":["December 25, 2020"],"phase":["Phase 2/Phase 3"],"trial_arms":["standard care | standard care + methylprednisolone therapy"],"cond":["Respiratory Infection Virus"]},{"nct_id":["NCT04251767"],"intervention":["Observational group"],"study_type":["Interventional"],"start_date":["February 5, 2020"],"compl_date":["April 30, 2020"],"phase":["N/A"],"trial_arms":["Observational group | Control group"],"cond":["COVID-19 Complicated With Refractory Intestinal Infections"]},{"nct_id":["NCT04251871"],"intervention":["Conventional medicines and TCMs granules"],"study_type":["Interventional"],"start_date":["January 22, 2020"],"compl_date":["January 22, 2021"],"phase":["N/A"],"trial_arms":["Conventional medicines and TCMs granules | Conventional medicines"],"cond":["Pneumonia Caused by Human Coronavirus (Disorder)"]},{"nct_id":["NCT04252118"],"intervention":["MSCs Treatment Group"],"study_type":["Interventional"],"start_date":["January 27, 2020"],"compl_date":["December 2021"],"phase":["Phase 1"],"trial_arms":["MSCs Treatment Group | Conventional Control Group"],"cond":["2019 Novel Coronavirus Pneumonia"]},{"nct_id":["NCT04252274"],"intervention":["Darunavir, Cobicistat and conventional treatments"],"study_type":["Interventional"],"start_date":["January 30, 2020"],"compl_date":["December 31, 2020"],"phase":["Phase 3"],"trial_arms":["Darunavir, Cobicistat and conventional treatments | Conventional treatments"],"cond":["Pneumonia, Pneumocystis"]},{"nct_id":["NCT04252274"],"intervention":["Darunavir, Cobicistat and conventional treatments"],"study_type":["Interventional"],"start_date":["January 30, 2020"],"compl_date":["December 31, 2020"],"phase":["Phase 3"],"trial_arms":["Darunavir, Cobicistat and conventional treatments | Conventional treatments"],"cond":["Coronavirus"]},{"nct_id":["NCT04252885"],"intervention":["Group A-Standard treatment+lopinavir/ritonavir"],"study_type":["Interventional"],"start_date":["January 28, 2020"],"compl_date":["July 31, 2020"],"phase":["Phase 4"],"trial_arms":["Group A-Standard treatment+lopinavir/ritonavir | Group B-Standard treatment+arbidol | Group C-Standard treatment"],"cond":["Coronavirus Infections"]},{"nct_id":["NCT04260594"],"intervention":["Arbidol tablets + basic treatment"],"study_type":["Interventional"],"start_date":["February 7, 2020"],"compl_date":["December 30, 2020"],"phase":["Phase 4"],"trial_arms":["Arbidol tablets + basic treatment | basic treatment"],"cond":["2019-nCoV"]},{"nct_id":["NCT04261517"],"intervention":["Hydroxychloroquine and conventional treatments"],"study_type":["Interventional"],"start_date":["February 6, 2020"],"compl_date":["December 31, 2020"],"phase":["Phase 3"],"trial_arms":["Hydroxychloroquine and conventional treatments | Conventional treatments"],"cond":["Pneumonia, Pneumocystis"]},{"nct_id":["NCT04261517"],"intervention":["Hydroxychloroquine and conventional treatments"],"study_type":["Interventional"],"start_date":["February 6, 2020"],"compl_date":["December 31, 2020"],"phase":["Phase 3"],"trial_arms":["Hydroxychloroquine and conventional treatments | Conventional treatments"],"cond":["Coronavirus"]},{"nct_id":["NCT04261907"],"intervention":["ASC09/ritonavir group"],"study_type":["Interventional"],"start_date":["February 7, 2020"],"compl_date":["June 30, 2020"],"phase":["N/A"],"trial_arms":["ASC09/ritonavir group | lopinavir/ritonavir group"],"cond":["2019-nCoV"]},{"nct_id":["NCT04264533"],"intervention":["VC"],"study_type":["Interventional"],"start_date":["February 14, 2020"],"compl_date":["September 30, 2020"],"phase":["Phase 2"],"trial_arms":["VC | Sterile water for injection"],"cond":["Vitamin C"]},{"nct_id":["NCT04264533"],"intervention":["VC"],"study_type":["Interventional"],"start_date":["February 14, 2020"],"compl_date":["September 30, 2020"],"phase":["Phase 2"],"trial_arms":["VC | Sterile water for injection"],"cond":["Pneumonia, Viral"]},{"nct_id":["NCT04264533"],"intervention":["VC"],"study_type":["Interventional"],"start_date":["February 14, 2020"],"compl_date":["September 30, 2020"],"phase":["Phase 2"],"trial_arms":["VC | Sterile water for injection"],"cond":["Pneumonia, Ventilator-Associated"]},{"nct_id":["NCT04269525"],"intervention":["pneumonia"],"study_type":["Interventional"],"start_date":["February 6, 2020"],"compl_date":["September 30, 2020"],"phase":["Phase 2"],"trial_arms":["pneumonia"],"cond":["Pneumonia, Viral"]},{"nct_id":["NCT04269525"],"intervention":["pneumonia"],"study_type":["Interventional"],"start_date":["February 6, 2020"],"compl_date":["September 30, 2020"],"phase":["Phase 2"],"trial_arms":["pneumonia"],"cond":["Pneumonia, Ventilator-Associated"]},{"nct_id":["NCT04273321"],"intervention":["Pred group"],"study_type":["Interventional"],"start_date":["February 14, 2020"],"compl_date":["May 30, 2020"],"phase":["N/A"],"trial_arms":["Pred group | Con group"],"cond":["COVID-19"]},{"nct_id":["NCT04273321"],"intervention":["Pred group"],"study_type":["Interventional"],"start_date":["February 14, 2020"],"compl_date":["May 30, 2020"],"phase":["N/A"],"trial_arms":["Pred group | Con group"],"cond":["Novel Coronavirus Pneumonia"]},{"nct_id":["NCT04273529"],"intervention":["Control group"],"study_type":["Interventional"],"start_date":["February 20, 2020"],"compl_date":["June 30, 2020"],"phase":["Phase 2"],"trial_arms":["Control group | Thalidomide group"],"cond":["COVID-19 Thalidomide"]},{"nct_id":["NCT04273581"],"intervention":["Control group"],"study_type":["Interventional"],"start_date":["February 18, 2020"],"compl_date":["May 30, 2020"],"phase":["Phase 2"],"trial_arms":["Control group | Thalidomide group"],"cond":["COVID-19 Thalidomide"]},{"nct_id":["NCT04273646"],"intervention":["UC-MSCs Treatment Group"],"study_type":["Interventional"],"start_date":["February 16, 2020"],"compl_date":["February 15, 2022"],"phase":["N/A"],"trial_arms":["UC-MSCs Treatment Group | Conventional Control Group"],"cond":["2019 Novel Coronavirus Pneumonia"]},{"nct_id":["NCT04273646"],"intervention":["UC-MSCs Treatment Group"],"study_type":["Interventional"],"start_date":["February 16, 2020"],"compl_date":["February 15, 2022"],"phase":["N/A"],"trial_arms":["UC-MSCs Treatment Group | Conventional Control Group"],"cond":["COVID-19"]},{"nct_id":["NCT04273763"],"intervention":["Group A"],"study_type":["Interventional"],"start_date":["February 16, 2020"],"compl_date":["April 30, 2020"],"phase":["N/A"],"trial_arms":["Group A | Group B"],"cond":["Novel Coronavirus Pneumonia"]},{"nct_id":["NCT04273763"],"intervention":["Group A"],"study_type":["Interventional"],"start_date":["February 16, 2020"],"compl_date":["April 30, 2020"],"phase":["N/A"],"trial_arms":["Group A | Group B"],"cond":["2019-nCoV"]},{"nct_id":["NCT04275388"],"intervention":["Xiyanping injection +other drugs"],"study_type":["Interventional"],"start_date":["February 14, 2020"],"compl_date":["December 14, 2021"],"phase":["N/A"],"trial_arms":["Xiyanping injection +other drugs | other drugs"],"cond":["2019 Novel Coronavirus Pneumonia"]},{"nct_id":["NCT04275414"],"intervention":["bevacizumab plus regular therapy"],"study_type":["Interventional"],"start_date":["February 2020"],"compl_date":["May 2020"],"phase":["Phase 2/Phase 3"],"trial_arms":["bevacizumab plus regular therapy"],"cond":["Coronavirus Infections"]},{"nct_id":["NCT04276688"],"intervention":["Study group"],"study_type":["Interventional"],"start_date":["February 10, 2020"],"compl_date":["July 31, 2022"],"phase":["Phase 2"],"trial_arms":["Study group | Control group"],"cond":["Novel Coronavirus Infection"]},{"nct_id":["NCT04276896"],"intervention":["pathogen-specific DC and CTLs"],"study_type":["Interventional"],"start_date":["March 24, 2020"],"compl_date":["December 31, 2024"],"phase":["Phase 1/Phase 2"],"trial_arms":["pathogen-specific DC and CTLs"],"cond":["Pathogen Infection Covid-19 Infection"]},{"nct_id":["NCT04276987"],"intervention":["MSCs-derived Exosomes Treatment Group"],"study_type":["Interventional"],"start_date":["February 15, 2020"],"compl_date":["July 31, 2020"],"phase":["Phase 1"],"trial_arms":["MSCs-derived Exosomes Treatment Group"],"cond":["Coronavirus"]},{"nct_id":["NCT04278963"],"intervention":["Yin Hu Qing Wen Decoction Group"],"study_type":["Interventional"],"start_date":["February 27, 2020"],"compl_date":["January 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Yin Hu Qing Wen Decoction Group | Yinhu Qingwen Decoction low-dose group | Integrated Chinese and Western Medicine group"],"cond":["CoVID-19"]},{"nct_id":["NCT04278963"],"intervention":["Yin Hu Qing Wen Decoction Group"],"study_type":["Interventional"],"start_date":["February 27, 2020"],"compl_date":["January 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Yin Hu Qing Wen Decoction Group | Yinhu Qingwen Decoction low-dose group | Integrated Chinese and Western Medicine group"],"cond":["Chinese Medicine"]},{"nct_id":["NCT04280224"],"intervention":["NK Cells Treatment Group"],"study_type":["Interventional"],"start_date":["February 20, 2020"],"compl_date":["December 30, 2020"],"phase":["Phase 1"],"trial_arms":["NK Cells Treatment Group | Conventional Control Group"],"cond":["Novel Coronavirus Pneumonia"]},{"nct_id":["NCT04280588"],"intervention":["Treatment group"],"study_type":["Interventional"],"start_date":["February 22, 2020"],"compl_date":["July 1, 2020"],"phase":["Phase 2"],"trial_arms":["Treatment group | Control group"],"cond":["Coronavirus Disease (COVID-19)"]},{"nct_id":["NCT04280705"],"intervention":["Placebo"],"study_type":["Interventional"],"start_date":["February 21, 2020"],"compl_date":["April 1, 2023"],"phase":["Phase 2"],"trial_arms":["Placebo | Remdesivir"],"cond":["Corona Virus Infection"]},{"nct_id":["NCT04281693"],"intervention":["Screening participants"],"study_type":["Interventional"],"start_date":["February 2020"],"compl_date":["March 2020"],"phase":["N/A"],"trial_arms":["Screening participants"],"cond":["Novel Coronavirus Infection Pneumonia"]},{"nct_id":["NCT04282902"],"intervention":["Pirfenidone group"],"study_type":["Interventional"],"start_date":["February 4, 2020"],"compl_date":["June 1, 2020"],"phase":["Phase 3"],"trial_arms":["Pirfenidone group | Standard treatment group"],"cond":["Novel Coronavirus Pneumonia"]},{"nct_id":["NCT04282902"],"intervention":["Pirfenidone group"],"study_type":["Interventional"],"start_date":["February 4, 2020"],"compl_date":["June 1, 2020"],"phase":["Phase 3"],"trial_arms":["Pirfenidone group | Standard treatment group"],"cond":["Pneumonia"]},{"nct_id":["NCT04282902"],"intervention":["Pirfenidone group"],"study_type":["Interventional"],"start_date":["February 4, 2020"],"compl_date":["June 1, 2020"],"phase":["Phase 3"],"trial_arms":["Pirfenidone group | Standard treatment group"],"cond":["Pirfenidone"]},{"nct_id":["NCT04283461"],"intervention":["Arm 1"],"study_type":["Interventional"],"start_date":["March 3, 2020"],"compl_date":["June 1, 2021"],"phase":["Phase 1"],"trial_arms":["Arm 1 | Arm 2 | Arm 3"],"cond":["Corona Virus Infection"]},{"nct_id":["NCT04283825"],"intervention":["Humanistic care"],"study_type":["Interventional"],"start_date":["February 22, 2020"],"compl_date":["May 15, 2020"],"phase":["N/A"],"trial_arms":["Humanistic care | Non-humanistic care"],"cond":["Coronavirus Disease 2019"]},{"nct_id":["NCT04283838"],"intervention":["Humanistic care"],"study_type":["Interventional"],"start_date":["February 22, 2020"],"compl_date":["May 15, 2020"],"phase":["N/A"],"trial_arms":["Humanistic care"],"cond":["Coronavirus Disease 2019"]},{"nct_id":["NCT04285190"],"intervention":["The T89 treatment group"],"study_type":["Interventional"],"start_date":["February 26, 2020"],"compl_date":["September 15, 2020"],"phase":["N/A"],"trial_arms":["The T89 treatment group | The blank control group"],"cond":["Coronavirus Disease 2019"]},{"nct_id":["NCT04285190"],"intervention":["The T89 treatment group"],"study_type":["Interventional"],"start_date":["February 26, 2020"],"compl_date":["September 15, 2020"],"phase":["N/A"],"trial_arms":["The T89 treatment group | The blank control group"],"cond":["Novel Coronavirus Pneumonia"]},{"nct_id":["NCT04286503"],"intervention":["Carrimycin"],"study_type":["Interventional"],"start_date":["February 23, 2020"],"compl_date":["February 28, 2021"],"phase":["Phase 4"],"trial_arms":["Carrimycin | lopinavir/ritonavir or Arbidol or chloroquine phosphate"],"cond":["Novel Coronavirus Infectious Disease (COVID-19)"]},{"nct_id":["NCT04287686"],"intervention":["rhACE2 group"],"study_type":["Interventional"],"start_date":["February 2020"],"compl_date":["April 2020"],"phase":["N/A"],"trial_arms":["rhACE2 group | Control group"],"cond":["COVID-19"]},{"nct_id":["NCT04288102"],"intervention":["Mesenchymal Stem Cells (MSCs)"],"study_type":["Interventional"],"start_date":["March 5, 2020"],"compl_date":["December 31, 2021"],"phase":["Phase 1/Phase 2"],"trial_arms":["Mesenchymal Stem Cells (MSCs) | Placebo"],"cond":["Corona Virus Disease 2019(COVID-19)"]},{"nct_id":["NCT04290858"],"intervention":["Nitric Oxide inhalation"],"study_type":["Interventional"],"start_date":["March 1, 2020"],"compl_date":["February 1, 2022"],"phase":["Phase 2"],"trial_arms":["Nitric Oxide inhalation | Control"],"cond":["Coronavirus Infections"]},{"nct_id":["NCT04290858"],"intervention":["Nitric Oxide inhalation"],"study_type":["Interventional"],"start_date":["March 1, 2020"],"compl_date":["February 1, 2022"],"phase":["Phase 2"],"trial_arms":["Nitric Oxide inhalation | Control"],"cond":["Pneumonia, Viral"]},{"nct_id":["NCT04290858"],"intervention":["Nitric Oxide inhalation"],"study_type":["Interventional"],"start_date":["March 1, 2020"],"compl_date":["February 1, 2022"],"phase":["Phase 2"],"trial_arms":["Nitric Oxide inhalation | Control"],"cond":["Dyspnea"]},{"nct_id":["NCT04290871"],"intervention":["Treatment Group"],"study_type":["Interventional"],"start_date":["March 1, 2020"],"compl_date":["March 1, 2022"],"phase":["Phase 2"],"trial_arms":["Treatment Group | Control Group"],"cond":["Coronavirus"]},{"nct_id":["NCT04290871"],"intervention":["Treatment Group"],"study_type":["Interventional"],"start_date":["March 1, 2020"],"compl_date":["March 1, 2022"],"phase":["Phase 2"],"trial_arms":["Treatment Group | Control Group"],"cond":["SARS (Severe Acute Respiratory Syndrome)"]},{"nct_id":["NCT04291053"],"intervention":["experimental group"],"study_type":["Interventional"],"start_date":["April 1, 2020"],"compl_date":["September 1, 2020"],"phase":["Phase 2/Phase 3"],"trial_arms":["experimental group | control group"],"cond":["COVID-19"]},{"nct_id":["NCT04291729"],"intervention":["Ganovo+ritonavir with or without interferon atomization"],"study_type":["Interventional"],"start_date":["February 17, 2020"],"compl_date":["April 30, 2020"],"phase":["Phase 4"],"trial_arms":["Ganovo+ritonavir with or without interferon atomization | Pegasys | Novaferon atomization | Lopinavir + ritonavir | Chinese medicine +interferon atomization"],"cond":["2019-nCoV Pneumonia"]},{"nct_id":["NCT04292730"],"intervention":["Remdesivir (RDV), 5 Days"],"study_type":["Interventional"],"start_date":["March 15, 2020"],"compl_date":["May 2020"],"phase":["Phase 3"],"trial_arms":["Remdesivir (RDV), 5 Days | Remdesivir, 10 Days | Continued SOC Therapy"],"cond":["COVID-19"]},{"nct_id":["NCT04292899"],"intervention":["Remdesivir (RDV), 5 Days"],"study_type":["Interventional"],"start_date":["March 6, 2020"],"compl_date":["May 2020"],"phase":["Phase 3"],"trial_arms":["Remdesivir (RDV), 5 Days | Remdesivir, 10 Days"],"cond":["COVID-19"]},{"nct_id":["NCT04293692"],"intervention":["UC-MSCs treatment group"],"study_type":["Interventional"],"start_date":["February 24, 2020"],"compl_date":["February 25, 2020"],"phase":["N/A"],"trial_arms":["UC-MSCs treatment group | Control group"],"cond":["COVID-19"]},{"nct_id":["NCT04293887"],"intervention":["Standard therapy + interferon therapy"],"study_type":["Interventional"],"start_date":["March 1, 2020"],"compl_date":["June 30, 2020"],"phase":["Early Phase 1"],"trial_arms":["Standard therapy + interferon therapy | Standard therapy + blank therapy"],"cond":["COVID-19"]},{"nct_id":["NCT04293887"],"intervention":["Standard therapy + interferon therapy"],"study_type":["Interventional"],"start_date":["March 1, 2020"],"compl_date":["June 30, 2020"],"phase":["Early Phase 1"],"trial_arms":["Standard therapy + interferon therapy | Standard therapy + blank therapy"],"cond":["Recombinant Human Interferon <U+03B1>1ß"]},{"nct_id":["NCT04295551"],"intervention":["Experimental group of ordinary COVID-19"],"study_type":["Interventional"],"start_date":["March 14, 2020"],"compl_date":["April 14, 2021"],"phase":["N/A"],"trial_arms":["Experimental group of ordinary COVID-19 | Control group of ordinary COVID-19 | Experimental group of severe COVID-19"],"cond":["COVID-19"]},{"nct_id":["NCT04296643"],"intervention":["Medical Mask"],"study_type":["Interventional"],"start_date":["April 1, 2020"],"compl_date":["January 1, 2021"],"phase":["N/A"],"trial_arms":["Medical Mask | N95 respirator"],"cond":["Coronavirus"]},{"nct_id":["NCT04296643"],"intervention":["Medical Mask"],"study_type":["Interventional"],"start_date":["April 1, 2020"],"compl_date":["January 1, 2021"],"phase":["N/A"],"trial_arms":["Medical Mask | N95 respirator"],"cond":["N95"]},{"nct_id":["NCT04296643"],"intervention":["Medical Mask"],"study_type":["Interventional"],"start_date":["April 1, 2020"],"compl_date":["January 1, 2021"],"phase":["N/A"],"trial_arms":["Medical Mask | N95 respirator"],"cond":["Medical Mask"]},{"nct_id":["NCT04299152"],"intervention":["Stem Cell Educator therapy treat patients with SARS-CoV-2"],"study_type":["Interventional"],"start_date":["April 10, 2020"],"compl_date":["November 10, 2020"],"phase":["Phase 2"],"trial_arms":["Stem Cell Educator therapy treat patients with SARS-CoV-2 | Conventional treatment of patients with SARS-CoV-2"],"cond":["Severe Acute Respiratory Syndrome (SARS) Pneumonia"]},{"nct_id":["NCT04299724"],"intervention":["Injection of Covid-19/aAPC vaccine"],"study_type":["Interventional"],"start_date":["February 15, 2020"],"compl_date":["December 31, 2024"],"phase":["Phase 1"],"trial_arms":["Injection of Covid-19/aAPC vaccine"],"cond":["Treat and Prevent Covid-19 Infection"]},{"nct_id":["NCT04302519"],"intervention":["Pulp mesenchymal stem cells"],"study_type":["Interventional"],"start_date":["March 5, 2020"],"compl_date":["July 30, 2021"],"phase":["Early Phase 1"],"trial_arms":["Pulp mesenchymal stem cells"],"cond":["COVID-19"]},{"nct_id":["NCT04303299"],"intervention":["Oseltamivir plus Chloroquin in Mild COVID19"],"study_type":["Interventional"],"start_date":["March 15, 2020"],"compl_date":["November 30, 2020"],"phase":["Phase 3"],"trial_arms":["Oseltamivir plus Chloroquin in Mild COVID19 | Lopinavir and Ritonavir plus Favipiravir | Lopinavir and Ritonavir plus Oseltamivir in mild COVID19 | Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19 | Favipiravir lopinavir /Ritonavir for mod. To severe | Darunavir /ritonavir oseltamivir chloroquine mod-severe | Darunavir /ritonavir favipiravir chloroquine mod-severe | Conventional Qurantine"],"cond":["Coronavirus Infections"]},{"nct_id":["NCT04303299"],"intervention":["Oseltamivir plus Chloroquin in Mild COVID19"],"study_type":["Interventional"],"start_date":["March 15, 2020"],"compl_date":["November 30, 2020"],"phase":["Phase 3"],"trial_arms":["Oseltamivir plus Chloroquin in Mild COVID19 | Lopinavir and Ritonavir plus Favipiravir | Lopinavir and Ritonavir plus Oseltamivir in mild COVID19 | Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19 | Favipiravir lopinavir /Ritonavir for mod. To severe | Darunavir /ritonavir oseltamivir chloroquine mod-severe | Darunavir /ritonavir favipiravir chloroquine mod-severe | Conventional Qurantine"],"cond":["COVID19"]},{"nct_id":["NCT04303507"],"intervention":["Chloroquine"],"study_type":["Interventional"],"start_date":["May 2020"],"compl_date":["May 2022"],"phase":["N/A"],"trial_arms":["Chloroquine | Placebo"],"cond":["COVID19"]},{"nct_id":["NCT04303507"],"intervention":["Chloroquine"],"study_type":["Interventional"],"start_date":["May 2020"],"compl_date":["May 2022"],"phase":["N/A"],"trial_arms":["Chloroquine | Placebo"],"cond":["Coronavirus"]},{"nct_id":["NCT04303507"],"intervention":["Chloroquine"],"study_type":["Interventional"],"start_date":["May 2020"],"compl_date":["May 2022"],"phase":["N/A"],"trial_arms":["Chloroquine | Placebo"],"cond":["Acute Respiratory Illnesses"]},{"nct_id":["NCT04304053"],"intervention":["No Intervention- SARS-CoV-2 surveillance"],"study_type":["Interventional"],"start_date":["March 15, 2020"],"compl_date":["July 15, 2020"],"phase":["Phase 3"],"trial_arms":["No Intervention- SARS-CoV-2 surveillance | Testing, treatment and prophylaxis of SARS-CoV-2"],"cond":["COVID-19"]},{"nct_id":["NCT04304313"],"intervention":["Sildenafil citrate tablets"],"study_type":["Interventional"],"start_date":["February 9, 2020"],"compl_date":["November 9, 2020"],"phase":["Phase 3"],"trial_arms":["Sildenafil citrate tablets"],"cond":["COVID-19"]},{"nct_id":["NCT04305106"],"intervention":["Bevacizumab Group"],"study_type":["Interventional"],"start_date":["March 12, 2020"],"compl_date":["May 31, 2020"],"phase":["N/A"],"trial_arms":["Bevacizumab Group | Control Group"],"cond":["COVID-19 Pneumonia"]},{"nct_id":["NCT04305457"],"intervention":["Nitric Oxide inhalation"],"study_type":["Interventional"],"start_date":["March 13, 2020"],"compl_date":["April 1, 2022"],"phase":["Phase 2"],"trial_arms":["Nitric Oxide inhalation | Control"],"cond":["Coronavirus Infections"]},{"nct_id":["NCT04305457"],"intervention":["Nitric Oxide inhalation"],"study_type":["Interventional"],"start_date":["March 13, 2020"],"compl_date":["April 1, 2022"],"phase":["Phase 2"],"trial_arms":["Nitric Oxide inhalation | Control"],"cond":["Pneumonia, Viral"]},{"nct_id":["NCT04305457"],"intervention":["Nitric Oxide inhalation"],"study_type":["Interventional"],"start_date":["March 13, 2020"],"compl_date":["April 1, 2022"],"phase":["Phase 2"],"trial_arms":["Nitric Oxide inhalation | Control"],"cond":["Acute Respiratory Distress Syndrome"]},{"nct_id":["NCT04306055"],"intervention":["Questionnaire with precaution information"],"study_type":["Interventional"],"start_date":["March 12, 2020"],"compl_date":["April 9, 2020"],"phase":["N/A"],"trial_arms":["Questionnaire with precaution information | Questionnaire without precaution information | No questionnaire group"],"cond":["Blood Donation"]},{"nct_id":["NCT04306393"],"intervention":["Treatment Group"],"study_type":["Interventional"],"start_date":["March 10, 2020"],"compl_date":["March 10, 2022"],"phase":["Phase 2"],"trial_arms":["Treatment Group | Control Group"],"cond":["SARS (Severe Acute Respiratory Syndrome)"]},{"nct_id":["NCT04306393"],"intervention":["Treatment Group"],"study_type":["Interventional"],"start_date":["March 10, 2020"],"compl_date":["March 10, 2022"],"phase":["Phase 2"],"trial_arms":["Treatment Group | Control Group"],"cond":["Coronavirus"]},{"nct_id":["NCT04307693"],"intervention":["Lopinavir/ritonavir"],"study_type":["Interventional"],"start_date":["March 11, 2020"],"compl_date":["May 2020"],"phase":["Phase 2"],"trial_arms":["Lopinavir/ritonavir | Hydroxychloroquine | Control"],"cond":["COVID-19"]},{"nct_id":["NCT04308317"],"intervention":["Tetrandrine Cohort"],"study_type":["Interventional"],"start_date":["March 5, 2020"],"compl_date":["May 1, 2021"],"phase":["Phase 4"],"trial_arms":["Tetrandrine Cohort | Control Cohort"],"cond":["Corona Virus Disease 2019,COVID-19"]},{"nct_id":["NCT04308668"],"intervention":["Treatment"],"study_type":["Interventional"],"start_date":["March 17, 2020"],"compl_date":["May 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Treatment | Placebo"],"cond":["Corona Virus Infection"]},{"nct_id":["NCT04308668"],"intervention":["Treatment"],"study_type":["Interventional"],"start_date":["March 17, 2020"],"compl_date":["May 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Treatment | Placebo"],"cond":["Acute Respiratory Distress Syndrome"]},{"nct_id":["NCT04308668"],"intervention":["Treatment"],"study_type":["Interventional"],"start_date":["March 17, 2020"],"compl_date":["May 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Treatment | Placebo"],"cond":["SARS-CoV Infection"]},{"nct_id":["NCT04310228"],"intervention":["Favipiravir Combined With Tocilizumab group"],"study_type":["Interventional"],"start_date":["March 8, 2020"],"compl_date":["May 2020"],"phase":["N/A"],"trial_arms":["Favipiravir Combined With Tocilizumab group | Favipiravir group | Tocilizumab group"],"cond":["COVID-19"]},{"nct_id":["NCT04310865"],"intervention":["Yinhu Qingwen Granula Group"],"study_type":["Interventional"],"start_date":["March 20, 2020"],"compl_date":["June 30, 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Yinhu Qingwen Granula Group | Yinhu Qingwen Granula Low-dose Group"],"cond":["COVID-19"]},{"nct_id":["NCT04310865"],"intervention":["Yinhu Qingwen Granula Group"],"study_type":["Interventional"],"start_date":["March 20, 2020"],"compl_date":["June 30, 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Yinhu Qingwen Granula Group | Yinhu Qingwen Granula Low-dose Group"],"cond":["Severe Pneumonia"]},{"nct_id":["NCT04310865"],"intervention":["Yinhu Qingwen Granula Group"],"study_type":["Interventional"],"start_date":["March 20, 2020"],"compl_date":["June 30, 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Yinhu Qingwen Granula Group | Yinhu Qingwen Granula Low-dose Group"],"cond":["Chinese Medicine"]},{"nct_id":["NCT04311177"],"intervention":["Losartan"],"study_type":["Interventional"],"start_date":["March 16, 2020"],"compl_date":["April 1, 2021"],"phase":["Phase 2"],"trial_arms":["Losartan | Placebo"],"cond":["Corona Virus Infection"]},{"nct_id":["NCT04311177"],"intervention":["Losartan"],"study_type":["Interventional"],"start_date":["March 16, 2020"],"compl_date":["April 1, 2021"],"phase":["Phase 2"],"trial_arms":["Losartan | Placebo"],"cond":["Acute Respiratory Distress Syndrome"]},{"nct_id":["NCT04311177"],"intervention":["Losartan"],"study_type":["Interventional"],"start_date":["March 16, 2020"],"compl_date":["April 1, 2021"],"phase":["Phase 2"],"trial_arms":["Losartan | Placebo"],"cond":["SARS-CoV Infection"]},{"nct_id":["NCT04311697"],"intervention":["Aviptadil IV followed by IV + Nebulization"],"study_type":["Interventional"],"start_date":["April 2020"],"compl_date":["September 2020"],"phase":["Phase 2"],"trial_arms":["Aviptadil IV followed by IV + Nebulization | Nebulized Aviptadil followed by IV Aviptadil"],"cond":["Acute Respiratory Distress Syndrome"]},{"nct_id":["NCT04311697"],"intervention":["Aviptadil IV followed by IV + Nebulization"],"study_type":["Interventional"],"start_date":["April 2020"],"compl_date":["September 2020"],"phase":["Phase 2"],"trial_arms":["Aviptadil IV followed by IV + Nebulization | Nebulized Aviptadil followed by IV Aviptadil"],"cond":["Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)"]},{"nct_id":["NCT04311697"],"intervention":["Aviptadil IV followed by IV + Nebulization"],"study_type":["Interventional"],"start_date":["April 2020"],"compl_date":["September 2020"],"phase":["Phase 2"],"trial_arms":["Aviptadil IV followed by IV + Nebulization | Nebulized Aviptadil followed by IV Aviptadil"],"cond":["Corona Virus Infection"]},{"nct_id":["NCT04312009"],"intervention":["Losartan"],"study_type":["Interventional"],"start_date":["March 16, 2020"],"compl_date":["April 1, 2021"],"phase":["Phase 2"],"trial_arms":["Losartan | Placebo"],"cond":["Corona Virus Infection"]},{"nct_id":["NCT04312009"],"intervention":["Losartan"],"study_type":["Interventional"],"start_date":["March 16, 2020"],"compl_date":["April 1, 2021"],"phase":["Phase 2"],"trial_arms":["Losartan | Placebo"],"cond":["Acute Respiratory Distress Syndrome"]},{"nct_id":["NCT04312009"],"intervention":["Losartan"],"study_type":["Interventional"],"start_date":["March 16, 2020"],"compl_date":["April 1, 2021"],"phase":["Phase 2"],"trial_arms":["Losartan | Placebo"],"cond":["SARS-CoV Infection"]},{"nct_id":["NCT04312243"],"intervention":["Treatment Group"],"study_type":["Interventional"],"start_date":["March 20, 2020"],"compl_date":["March 20, 2022"],"phase":["Phase 2"],"trial_arms":["Treatment Group | Control Group"],"cond":["Coronavirus Infections"]},{"nct_id":["NCT04312243"],"intervention":["Treatment Group"],"study_type":["Interventional"],"start_date":["March 20, 2020"],"compl_date":["March 20, 2022"],"phase":["Phase 2"],"trial_arms":["Treatment Group | Control Group"],"cond":["Healthcare Associated Infection"]},{"nct_id":["NCT04312997"],"intervention":["PUL-042 Inhalation Solution"],"study_type":["Interventional"],"start_date":["April 2020"],"compl_date":["October 2020"],"phase":["Phase 2"],"trial_arms":["PUL-042 Inhalation Solution | Sterile normal saline for inhalation"],"cond":["COVID-19"]},{"nct_id":["NCT04313023"],"intervention":["PUL-042 Inhalation Solution"],"study_type":["Interventional"],"start_date":["April 2020"],"compl_date":["October 2020"],"phase":["Phase 2"],"trial_arms":["PUL-042 Inhalation Solution | Sterile normal saline for inhalation"],"cond":["COVID-19"]},{"nct_id":["NCT04313127"],"intervention":["Low-dose Group"],"study_type":["Interventional"],"start_date":["March 19, 2020"],"compl_date":["December 20, 2022"],"phase":["Phase 1"],"trial_arms":["Low-dose Group | Middle-dose Group | High-dose Group"],"cond":["COVID-19"]},{"nct_id":["NCT04313322"],"intervention":["WJ-MSCs"],"study_type":["Interventional"],"start_date":["March 16, 2020"],"compl_date":["September 30, 2020"],"phase":["Phase 1"],"trial_arms":["WJ-MSCs"],"cond":["Use of Stem Cells for COVID-19 Treatment"]},{"nct_id":["NCT04315298"],"intervention":["Sarilumab high dose"],"study_type":["Interventional"],"start_date":["March 16, 2020"],"compl_date":["March 16, 2021"],"phase":["Phase 2/Phase 3"],"trial_arms":["Sarilumab high dose | Sarilumab low dose | Placebo"],"cond":["COVID-19"]},{"nct_id":["NCT04315896"],"intervention":["treatment"],"study_type":["Interventional"],"start_date":["March 23, 2020"],"compl_date":["March 22, 2021"],"phase":["Phase 3"],"trial_arms":["treatment | placebo"],"cond":["COVID-19"]},{"nct_id":["NCT04315896"],"intervention":["treatment"],"study_type":["Interventional"],"start_date":["March 23, 2020"],"compl_date":["March 22, 2021"],"phase":["Phase 3"],"trial_arms":["treatment | placebo"],"cond":["Severe Acute Respiratory Syndrome"]},{"nct_id":["NCT04315948"],"intervention":["Remdesivir"],"study_type":["Interventional"],"start_date":["March 2020"],"compl_date":["March 2023"],"phase":["Phase 3"],"trial_arms":["Remdesivir | Lopinavir/ritonavir | Lopinavir/ritonavir plus Interferon ß-1a | Standard of care"],"cond":["Corona Virus Infection"]},{"nct_id":["NCT04315987"],"intervention":["NestCell®"],"study_type":["Interventional"],"start_date":["April 2020"],"compl_date":["June 2020"],"phase":["Phase 1"],"trial_arms":["NestCell®"],"cond":["COVID-19 Pneumonia"]},{"nct_id":["NCT04316377"],"intervention":["Treatment"],"study_type":["Interventional"],"start_date":["March 23, 2020"],"compl_date":["March 3, 2025"],"phase":["Phase 4"],"trial_arms":["Treatment | No Treatment"],"cond":["Corona Virus Infection"]},{"nct_id":["NCT04316728"],"intervention":["negative Patients"],"study_type":["Interventional"],"start_date":["March 2020"],"compl_date":["November 2020"],"phase":["N/A"],"trial_arms":["negative Patients"],"cond":["Coronavirus Infections"]},{"nct_id":["NCT04317040"],"intervention":["CD24Fc Treatment"],"study_type":["Interventional"],"start_date":["May 2020"],"compl_date":["May 2022"],"phase":["Phase 3"],"trial_arms":["CD24Fc Treatment | Placebo"],"cond":["Severe Coronavirus Disease (COVID-19)"]},{"nct_id":["NCT04317092"],"intervention":["tocilizumab treatment"],"study_type":["Interventional"],"start_date":["March 19, 2020"],"compl_date":["December 19, 2022"],"phase":["Phase 2"],"trial_arms":["tocilizumab treatment"],"cond":["COVID-19 Pneumonia"]}]
